Literature DB >> 8334811

Clenbuterol, a beta-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients.

C A Maltin1, M I Delday, J S Watson, S D Heys, I M Nevison, I K Ritchie, P H Gibson.   

Abstract

1. The sympathomimetic agent clenbuterol has a muscle-specific anabolic effect in normal and wasted muscles from animals. This trial was designed to examine the effect of the drug on the recovery of muscle strength and area after open medial meniscectomy. 2. A double-blind, completely randomized, placebo-controlled study was carried out on 20 healthy male patients. Muscle strength and cross-sectional area were determined before and after surgery. Patients were treated with drug or placebo for 4 weeks postoperatively and there was a 2 week washout period. 3. The results suggest that, in the operated leg, clenbuterol treatment is associated with a more rapid rehabilitation of strength in knee extensor muscles; in the unoperated leg, knee extensor strength increased above the initial values after 6 weeks (P = 0.01). However, in terms of absolute strength the differences were not significant between the two groups. 4. It is concluded that the data lend support to the proposition that clenbuterol has therapeutic potential in the treatment of muscle-wasting conditions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8334811     DOI: 10.1042/cs0840651

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  21 in total

Review 1.  Athletes and doping: effects of drugs on the respiratory system.

Authors:  P N Dekhuijzen; H A Machiels; L M Heunks; H F van der Heijden; R H van Balkom
Journal:  Thorax       Date:  1999-11       Impact factor: 9.139

2.  Gym and tonic: a profile of 100 male steroid users.

Authors:  N A Evans
Journal:  Br J Sports Med       Date:  1997-03       Impact factor: 13.800

Review 3.  Disuse of the musculo-skeletal system in space and on earth.

Authors:  M V Narici; M D de Boer
Journal:  Eur J Appl Physiol       Date:  2010-07-09       Impact factor: 3.078

Review 4.  A review of the drug treatment of cachexia associated with cancer.

Authors:  B Gagnon; E Bruera
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

Review 5.  Drugs and sport. Research findings and limitations.

Authors:  P M Clarkson; H S Thompson
Journal:  Sports Med       Date:  1997-12       Impact factor: 11.136

6.  Effects of clenbuterol and ICI118551, a selective beta 2-antagonist, on the growth of skeletal muscle of suckling rats.

Authors:  R H Morton; E T Agbenyega; P A Hatton; A C Wareham
Journal:  Pflugers Arch       Date:  1995-12       Impact factor: 3.657

7.  Phase I/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy.

Authors:  C A Greig; N Johns; C Gray; A MacDonald; N A Stephens; R J E Skipworth; M Fallon; L Wall; G M Fox; K C H Fearon
Journal:  Support Care Cancer       Date:  2014-01-04       Impact factor: 3.603

8.  Correction of Biochemical Abnormalities and Improved Muscle Function in a Phase I/II Clinical Trial of Clenbuterol in Pompe Disease.

Authors:  Dwight D Koeberl; Laura E Case; Edward C Smith; Crista Walters; Sang-Oh Han; Yanzhen Li; Wei Chen; Christoph P Hornik; Kim M Huffman; William E Kraus; Beth L Thurberg; David L Corcoran; Deeksha Bali; Nenad Bursac; Priya S Kishnani
Journal:  Mol Ther       Date:  2018-07-05       Impact factor: 11.454

9.  Acute clenbuterol overdose resulting in supraventricular tachycardia and atrial fibrillation.

Authors:  G Patrick Daubert; Vincent H Mabasa; Vivian W Y Leung; Cynthia Aaron
Journal:  J Med Toxicol       Date:  2007-06

10.  Regulation of SMN protein stability.

Authors:  Barrington G Burnett; Eric Muñoz; Animesh Tandon; Deborah Y Kwon; Charlotte J Sumner; Kenneth H Fischbeck
Journal:  Mol Cell Biol       Date:  2008-12-22       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.